MedTrace Logo

Avelumab, Palbociclib and Axitinib in Advanced RCC

NCT05176288 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-09-07

No results posted yet for this study

Summary

The aim of this study is to see whether the combination of 3 drugs (axitinib, avelumab and palbociclib) is safe and effective in slowing down the growth of advanced clear cell renal cell carcinoma (ccRCC) in patients that have not received any prior systemic treatment.

The names of the study drug involved in this study are/is:

* Axitinib
* Avelumab
* Palbociclib

Conditions

  • Advanced Clear Cell Renal Cell Carcinoma

Interventions

DRUG

Axitinib

Taken Orally

DRUG

Palbociclib

Taken Orally

DRUG

Avelumab

Intravenous infusion

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Bradley A. McGregor, MD

    lead OTHER

Principal Investigators

  • Bradley McGregor, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-31
Primary Completion
2026-08-31
Completion
2027-08-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05176288 on ClinicalTrials.gov